Search

Thedevelopment of P-glycoprotein (P-gp) ligands remains of considerableinterest, mostly for investigating the protein’s structureand transport mechanism. In recent years, many different generationsof ligands have been tested for their ability to modulate P-gp activity.The aim of the present work is to perform SAR studies on tetrahydroisoquinolinederivatives in order to design potent and selective P-gp ligands.For this purpose, the effect of bioisosteric replacement and the roleof flexibility have been investigated, and four series of tetrahydroisoquinolineligands have been developed: (a) 2-aryloxazole bioisosteres, (b) elongatedanalogues, (c) 2H-chromene, and (d) 2-biphenyl derivatives.The results showed that both 2-biphenyl derivative 20band elongated derivative 6gbehaved as strong P-gpsubstrates. In conclusion, important aspects for developing potentand selective P-gp ligands have been highlighted, providing a solidstarting point for further optimization. [ABSTRACT FROM AUTHOR]

CSCs are responsible for the high rate of recurrence and chemoresistance of different types of cancer. The current antineoplastic agents able to inhibit bulk replicating cancer cells and radiation treatment are not efficacious toward CSCs since this subpopulation has several intrinsic mechanisms of resistance. Among these mechanisms, the expression of ATP-Binding Cassette (ABC) transporters family and the activation of different signaling pathways (such as Wnt/ß-catenin signaling, Hedgehog, Notch, Akt/PKB) are reported. Therefore, considering ABC transporters expression on CSCs membranes, compounds able to modulate MDR could induce cytotoxicity in these cells disclosing an exciting and alternative strategy for targeting CSCs in tumor therapy. The next challenge in the cure of cancer relapse may be a multimodal strategy, an approach where specific CSCs targeting drugs exert simultaneously the ability to circumvent tumor drug resistance (ABC transporters modulation) and cytotoxic activity toward CSCs and the corresponding differentiated tumor cells. The efficacy of suggested multimodal strategy could be probed by using several scaffolds active toward MDR pumps on CSCs isolated by tumor specimens. [ABSTRACT FROM AUTHOR]

Multidrug resistance (MDR) is a complex phenomenon principally due to the overexpression of some transmembrane proteins belonging to the ATP binding cassette (ABC) transporter family. Among these transporters, P-glycoprotein (P-gp) is mostly involved in MDR and its overexpression is the major cause of cancer therapy failure. The classical approach used to overcome MDR is the co-administration of a P-gp inhibitor and the classic antineoplastic drugs, although the resultswere often unsatisfactory. Different classes of P-gp ligands have been developed and, among them,Tariquidar has been extensively studied both in vitro and in vivo. AlthoughTariquidar has been considered for several years as the lead compound for the development of P-gp inhibitors, recent studies demonstrated it to be a substrate and inhibitor, in a dose-dependent manner. Moreover, Tariquidar structure- activity relationship studies were difficult to carry out because of the complexity of the structure that does not allow establishing the role of each moiety for P-gp activity. For this purpose, SMALL molecules bearing different scaffolds such as tetralin, biphenyl, arylthiazole, furoxane, furazan have been developed. Many of these ligands have been tested both in in vitro assays and in in vivo PET studies. These preliminary evaluations lead to obtain a library of P-gp interacting agents useful to conjugate chemotherapeutic agents displaying reduced pharmacological activity and appropriate small molecules. These molecules could get over the limits due to the antineoplastic-P-gp inhibitor co-administration since pharmacokinetic and pharmacodynamic profiles are related to a dual innovative drug [ABSTRACT FROM AUTHOR]